Nasef A, Ashammakhi N, Fouillard L
EA 1638: Hematologie, Faculté de médicine Saint Antoine, UPMC, Paris 6, France.
Regen Med. 2008 Jul;3(4):531-46. doi: 10.2217/17460751.3.4.531.
Co-transplantation of mesenchymal stem cells (MSCs) and hematopoietic stem cells ameliorate hematopoietic reconstitution and induce tolerance. The immunomodulatory properties of MSCs have been demonstrated both in vivo and in vitro. MSCs can modulate function of immune cells such as T lymphocytes, antigen-presenting cells and natural killer cells. However, it is unknown whether MSCs given to patients that have undergone HSC transplantation could alleviate graft versus leukemia effect or could increase the risk of the infection. Proper characterization of MSC immunomodulatory mechanisms are crucial to anticipate the possible effect of MSC in the host. In the current report, interesting and contradictory results in the literature are reviewed in an attempt to understand the underlying mechanism. Differences in experimental designs and models used seem to be the underlying causes of discrepancy in reported results. Results of the few in vivo studies are controversial and further clinical studies are needed to confirm the efficiency and safety of MSCs in transplantation management.
间充质干细胞(MSCs)与造血干细胞的共移植可改善造血重建并诱导免疫耐受。MSCs的免疫调节特性已在体内和体外得到证实。MSCs可调节免疫细胞如T淋巴细胞、抗原呈递细胞和自然杀伤细胞的功能。然而,对于接受造血干细胞移植的患者给予MSCs是否能减轻移植物抗白血病效应或增加感染风险尚不清楚。正确表征MSCs的免疫调节机制对于预测MSCs在宿主中的可能作用至关重要。在本报告中,对文献中有趣且相互矛盾的结果进行了综述,以试图理解其潜在机制。所用实验设计和模型的差异似乎是报告结果存在差异的根本原因。少数体内研究的结果存在争议,需要进一步的临床研究来证实MSCs在移植管理中的有效性和安全性。